ArticleVirchows Archiv : an international journal of pathology2026
Expression of glycolytic markers in cancer and stromal cells of treatment-naïve and neoadjuvantly treated pancreatic ductal adenocarcinoma.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
[18F]-Fluoro-2-deoxyglucose positron emission tomography (FDG-PET) has been introduced as a method for response evaluation following neoadjuvant chemotherapy in pancreatic cancer. Glycolytic activity detected by FDG-PET is deemed to correlate with the residual cancer burden after treatment, but the expression of key glycolytic markers in cancer and stromal cells of pancreatic cancer after treatment remains unknown. The current study aimed to investigate the expression and inter-/intratumour heterogeneity of glucose transporter 1 (Glut1) and monocarboxylate transporter 4 (MCT4) in cancer cells and stroma of treatment-naïve and neoadjuvantly treated pancreatic cancer. Expression of Glut1 and MCT4 in cancer cells and stroma was investigated by immunohistochemistry in three tissue sections from 30 treatment-naïve and 30 neoadjuvantly treated pancreatic cancer tumours (total: 180 sections). An immunoreactive score was calculated as the percentage of positive cells multiplied with the intensity of labelling. The expression of glycolytic markers varied considerably between and within both treatment-naïve and neoadjuvantly treated tumours. In cancer cells, expression did not significantly differ between the groups, while in tumour stroma, the expression of glycolytic markers was significantly lower in neoadjuvantly treated compared to treatment-naïve tumours. Maintained expression of key glycolytic markers in cancer cells following neoadjuvant therapy supports the use of FDG-PET for response evaluation in pancreatic cancer. However, tumour stroma, which in some cases markedly expresses Glut1 and MCT4, may constitute a potential source of error. Clinical trials correlating FDG-PET with immunohistochemical assessment of glycolysis in treatment-naïve and neoadjuvantly treated pancreatic cancer are needed.
Indexed as
Identifiers
41851513What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.